Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Investors Are Sitting on a Loss of 50% If They Invested Three Years Ago
Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Investors Are Sitting on a Loss of 50% If They Invested Three Years Ago
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. Unfortunately, that's been the case for longer term Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) shareholders, since the share price is down 51% in the last three years, falling well short of the market decline of around 27%.
作为投资者,值得努力确保您的整体投资组合超过市场平均水平。但是,你会发现有时你会购买该股,但其回报却低于市场平均水平。遗憾的是,长期持有南京证券股份股票的股东不断发现其股价下跌,而过去三年的股票下跌幅度超过27%,下跌了51%。
It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that.
值得评估公司的经济状况是否与这些不尽如人意的股东回报同时发展并步调一致,或者两者之间是否存在差异。因此,让我们来看看。
While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
尽管一些人继续教授有效市场假说,但已经证明市场是过度反应的动态系统,并且投资者并不总是理性的。通过比较每股收益(EPS)和股价的变化情况,我们可以了解投资者对公司的态度如何随着时间变化而变化。
Over the three years that the share price declined, Nanjing King-Friend Biochemical PharmaceuticalLtd's earnings per share (EPS) dropped significantly, falling to a loss. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.
在股票下跌的三年中,南京证券股份股票的每股收益(EPS)显著下降,降至亏损。由于该公司已陷入亏损位置,很难将EPS的变化与股价的变化进行比较。但是,我们可以说,在这种情况下,预计会看到股票价格下跌。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
该公司的每股收益(随时间的推移)如下图所示(单击可查看确切数字)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240629/0-dec14ab2d65998f9b04ef6ab43131b46-0-040879f3cabd159072b04a91b842bf5e.png/big)
Dive deeper into Nanjing King-Friend Biochemical PharmaceuticalLtd's key metrics by checking this interactive graph of Nanjing King-Friend Biochemical PharmaceuticalLtd's earnings, revenue and cash flow.
通过查看南京证券股份有限公司的收益,营业收入和现金流的交互式图表,深入了解其关键度量指标。
A Different Perspective
不同的观点
While it's never nice to take a loss, Nanjing King-Friend Biochemical PharmaceuticalLtd shareholders can take comfort that , including dividends,their trailing twelve month loss of 11% wasn't as bad as the market loss of around 16%. Given the total loss of 0.6% per year over five years, it seems returns have deteriorated in the last twelve months. While some investors do well specializing in buying companies that are struggling (but nonetheless undervalued), don't forget that Buffett said that 'turnarounds seldom turn'. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Nanjing King-Friend Biochemical PharmaceuticalLtd , and understanding them should be part of your investment process.
虽然损失从来不是什么好事,但南京证券股份有限公司的股东可以安慰自己,因为包括分红在内,他们过去十二个月的亏损仅为11%,而市场损失约为16%。在过去的五年中,每年的总损失率为0.6%,看来最近12个月的回报已经恶化。尽管一些投资者擅长于购买那些正在努力但估值合理的公司,但不要忘记巴菲特说的“转机很少是真正实现的”。尽管考虑市场条件可能对股票价格产生的不同影响很值得,但还有其他更重要的因素,比如投资风险的永恒威胁。我们已经确定了南京证券股份有限公司的1个警示信号,并加以理解是您投资过程的一部分。
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).
如果您喜欢与管理层一起购买股票,那么您可能会喜欢这个公司的免费列表。 (提示:其中许多公司不为人注意且具有吸引力的估值。)
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。